Japanese Pharma To Beef Up Transparency Policies In 2011 To Counter Public Concern - APEC Regulatory Conference
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Japanese pharma agreed to rollout updated in-house transparency guidelines in 2011 to strengthen compliance and improve the industry's public reputation
You may also be interested in...
Merck Tagged With Non-compliance In Japan For 3,600 Physicians' Unjustified Honoraria
TOKYO - Merck & Co. Inc - known as MSD in Japan - is trying to remediate internal oversight measurers quickly after it received a "strict warning" from an independent compliance council for improper payments to a total of 3,604 physicians in Japan between January 2009 and December 2010, which constituted violations of the Fair Competition Code
Merck Tagged With Non-compliance In Japan For 3,600 Physicians' Unjustified Honoraria
TOKYO - Merck & Co. Inc - known as MSD in Japan - is trying to remediate internal oversight measurers quickly after it received a "strict warning" from an independent compliance council for improper payments to a total of 3,604 physicians in Japan between January 2009 and December 2010, which constituted violations of the Fair Competition Code
RDPAC's Lobbying Efforts To Regulate China's Medical Representatives Likely To Pay Off This Year
SHANGHAI - As China rolls out its 12th five-year economic development plan, the R&D-based Pharmaceutical Association Committee (RDPAC) - an industry association representing multinational biopharma companies in China - is suggesting a friendlier regulatory environment for foreign companies